The standard treatment for squamous cell skin cancer that has invaded surrounding tissues typically involves surgery, possibly followed by radiotherapy. However, there's a risk of the cancer returning or spreading, prompting research into more effective treatments.
This trial examines the use of two drugs, V940 and pembrolizumab, alongside standard treatment. Pembrolizumab, an immunotherapy, aids the immune system in identifying and destroying cancer cells and is already used in treating certain cancers. V940, also an immunotherapy, is personalized based on the patient's cancer tissue and blood samples, aiming to train the immune system to target cancer early.
Participants are randomly assigned to one of three groups: standard treatment alone, standard treatment plus pembrolizumab, or standard treatment combined with both pembrolizumab and V940. The trial seeks to identify the most effective treatment combination, evaluate safety, understand side effects, and assess the treatment's impact on quality of life.
Treatment methods include pembrolizumab administered via a vein drip and V940 through muscle injections. The trial also involves regular scans and follow-ups to monitor the cancer's response to treatment. Additionally, researchers may request tissue and blood samples for further analysis to understand the treatment's effectiveness and the cancer's genetic makeup.
This international trial requires 1,012 participants and is conducted in a randomized manner, ensuring unbiased group allocation. The study represents a significant step forward in the search for more effective treatments for squamous cell skin cancer, potentially improving outcomes for patients worldwide.
